Epithalon Where to Buy: $2.50/mg Labelled, $2.59/mg Assayed

The same six apply whether you search Epithalon where to buy or Epithalon peptide where to buy, since the object is one 10 mg lyophilised vial either way. Four change what you can prove about the powder; two change the denominator.

Notice how little of that list is about the vendor. None of the six asks how long a seller has traded or how many reviews it carries. All six are documents, checkable in ten minutes without owning a balance.

A label weight is a target. A net content result is a measurement. The gap between them is where a per-milligram figure quietly becomes fiction, because nearly every price comparison in this market divides by the number printed on the box.

The Kovera certificate for batch 15-05260628 states the specification as 10 mg plus or minus 10 percent, a window of 9.00 mg to 11.00 mg. The measured result is 9.64 mg: 0.36 mg under the label and 0.64 mg above the floor, so it passes the specification while being less material than the label promises. Both statements are true at once, and printing the number is what lets you make either of them.

Run the division twice:

Nine cents a milligram is not a scandal, and it would have been undetectable had the vendor simply not measured. The reason to lead with it is that it shows which way this seller rounds when it has a choice, and the same vendor's February 2026 Selank certificate rounds the other way: that listing reports 12.29 mg against a 10 mg label, roughly 23 percent in the buyer's favour. Results landing on both sides of a label mean measuring rather than marketing. The severe version, where assayed mass falls far short, sits on our NAD+ buying page, where 1,000 mg labelled assays at 784 mg.

Only one certificate exists for this compound, unlike the neighbouring Russian peptides which each carry two. Here is every row, and what each does and does not settle.

• Purity, 99.312% against a stated minimum of 98%. Measured by reversed-phase HPLC on a C18 column with diode-array detection at 214 nm, the wavelength that reads the peptide bond. The headroom above the floor is 1.31 percentage points, which matters because a vial sitting exactly at specification would carry two percent non-target material.
• Identity confirmed by LC-MS. The mass check stops a purity figure from being a precise measurement of the wrong molecule.
• Endotoxin safety screen, PASS against a limit of 0.5 EU/mL. The weakest row on the document, and not because it failed. It prints a verdict rather than a value and names no method. The compendial reference for bacterial endotoxins testing is USP Chapter 85, and a certificate naming it and reporting a figure in EU/mL tells you how much headroom the lot had. PASS tells you only that it was somewhere under the line.
• Microbial sterility screen, no growth. A screen, which is a shorter and less demanding test than a compendial sterility procedure.
• Heavy metals, negative for arsenic, cadmium, lead and mercury. Reported as negative rather than as figures against limits, so again a verdict rather than a measurement.

Two details tie the document to a physical object. It prints report number KVR-2026-A36FF4 with an access code and a verification address at koveralabs.com, so it can be confirmed at the laboratory rather than only on the seller's site. And it records the cap colour as red and the crimp as silver, so the vial can be matched against the paper before anything is opened.

The regulatory position decides which channels can legally sell you anything, so it belongs in a buying guide. Epitalon is not on the 503A bulks list, and appears in none of category 1, 2 or 3 on the lists FDA updated on 14 May 2026. It was nominated, placed in category 2 under the interim policies, and then withdrawn by the nominator. FDA describes that table as covering substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators".

So the accurate sentence is that Epitalon sits on no current category list, and the common claim that it is a category 2 substance is stale rather than merely wrong. A compounding pharmacy has no lawful path to a bulk substance absent from the lists, which closes the prescription channel before a prescriber's willingness even arises.

What FDA did write about the compound is a testing statement, and it is worth quoting exactly once because it is the argument for weighting the certificate the way this page does:

Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

Aggregation is peptide molecules clustering into larger assemblies; peptide-related impurities are the truncated and modified sequences solid-phase synthesis leaves behind. Both are invisible in a vial and both are measurable, which is why a purity result with a specification beside it outweighs any discount here. The same regulatory paragraph, applied to a neighbouring Russian peptide, runs through our Semax buying page.

The supplier costed at the top, run through all six, with the evidence named so any disagreement is about the marking rather than the conclusion.

Five clear passes and one partial, and the partial matters more than its size suggests: those two rows speak to the only concern FDA has put in writing, and they are the two reported as verdicts rather than numbers.

One limitation covers the exercise. A certificate describes a sampled aliquot on a date, here 23 May 2026, before filling, capping and transit: evidence about a production run, not a guarantee about a vial. The method behind this scoring sits in our guide to dosing and sourcing references.

The last division turns a purchase into a working figure. What follows is laboratory handling arithmetic on a research material, not guidance for administering anything to a person.

Add 2 mL of diluent and the label basis gives 10 mg in 2 mL, which is 5 mg/mL. A U-100 syringe is graduated so 100 units equal 1 mL, so 2 mL is 200 units of graduations and 10 units is 0.10 mL, drawing 500 mcg.

Now do it on the measurement. The vial holds 9.64 mg, so 2 mL gives 4.82 mg/mL and the same 10 units draws 482 mcg. The shortfall is 18 mcg per 10 units, or 3.6 percent, exactly the shortfall on the fill weight, because dilution does not create material.

The third row is the practical payoff of a published net content. Because the vendor measured, the volume can be corrected: adding 1.93 mL rather than 2.00 mL puts the concentration back at 5.00 mg/mL, so the graduations mean what the label implied. Nobody working from a label weight alone can make that correction. The volume and syringe conventions used here are set out in our reconstitution guide and syringe measurement guide.

Two closing limits. A clean certificate speaks to chemistry and contamination, not to effect, and FDA's own sentence is that it lacks the information to know whether the substance would cause harm in humans. And the telomere and longevity claims driving demand here rest largely on one group's work, mostly in Russian, which makes them the reason people search rather than a finding this page endorses.